Filter

Tumor Types

Investigational Therapies

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Showing results

Phase III

BREAST

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

BREAST

GDC-0077
(PI3K inhibitor)

(RG6114)

BREAST

GASTROINTESTINAL

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

GASTROINTESTINAL

Bevacizumab
(anti-VEGF MAb)
 

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD/NECK

HEMATOLOGY

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)c

HEMATOLOGY

LUNG

Tiragolumab
(anti-TIGIT MAb)

(MTIG7192A, RG6058)

LUNG

MELANOMA

PAN TUMOR

SOLID TUMOR

Phase II

BREAST

GASTROINTESTINAL

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

Tiragolumab
(anti-TIGIT)

(MTIG7192A, RG6058)

GYNECOLOGIC

HEAD/NECK

HEMATOLOGY

Idasanutlin
(MDM2 inhibitor)

(RG7388)

HEMATOLOGY

Mosunetuzumab
(CD20 x CD3)

(RG7828)

HEMATOLOGY

Cobimetinib
(MEK inhibitor)

(RG7421)e

HEMATOLOGY

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)c

HEMATOLOGY

LUNG

MELANOMA

Individualized NeoAntigen Specific Immunotherapy (iNeST)

(RG6180)f

MELANOMA

PAN TUMOR

SOLID TUMOR

IL5/IL15Ra-Fc

(RG6323)

SOLID TUMOR

Phase I

BREAST

HER2 x CD3

(RG6194)

BREAST

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

BREAST

GENITOURINARY

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

BREAST

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD AND NECK

HEMATOLOGY

SOLID TUMOR

Selective estrogen receptor degrader (SERD) 3

(GDC-9545, RG6171)

BREAST

GASTROINTESTINAL

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

BREAST

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD AND NECK

HEMATOLOGY

SOLID TUMOR

Bevacizumab
(anti-VEGF MAb)
 

GASTROINTESTINAL

Cobimetinib
(MEK inhibitor)

(RG7421)f

GASTROINTESTINAL

HEMATOLOGY

GENITOURINARY

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

BREAST

GENITOURINARY

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

BREAST

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD AND NECK

HEMATOLOGY

SOLID TUMOR

FAPxIL2v FP

(RG7461)

GENITOURINARY

SOLID TUMOR

MELANOMA

GYNECOLOGIC

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

BREAST

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD AND NECK

HEMATOLOGY

SOLID TUMOR

HEAD/NECK

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

BREAST

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD AND NECK

HEMATOLOGY

SOLID TUMOR

HEMATOLOGY

Glofitamab

(RG6026)

HEMATOLOGY

Idasanutlin
(MDM2 inhibitor)

(RG7388)

HEMATOLOGY

Mosunetuzumab
(CD20 x CD3)

(RG7828)

HEMATOLOGY

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

BREAST

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD AND NECK

HEMATOLOGY

SOLID TUMOR

CD19x4-1BBL

(RG6076)

HEMATOLOGY

Cobimetinib
(MEK inhibitor)

(RG7421)f

GASTROINTESTINAL

HEMATOLOGY

FcRH5 x CD3

(RG6160)

HEMATOLOGY

Tiragolumab
(anti-TIGIT MAb)

(MTIG7192A, RG6058)

SOLID TUMOR

HEMATOLOGY

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)c

HEMATOLOGY

CD47 MAb

N/A

HEMATOLOGY

LUNG

PD1 x TIM3

(RG7769)

LUNG

MELANOMA

SOLID TUMOR

MELANOMA

FAPxIL2v FP

(RG7461)

GENITOURINARY

SOLID TUMOR

MELANOMA

PD1 x TIM3

(RG7769)

LUNG

MELANOMA

SOLID TUMOR

PAN TUMOR

SOLID TUMOR

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

BREAST

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD AND NECK

HEMATOLOGY

SOLID TUMOR

FAPxIL2v FP

(RG7461)

GENITOURINARY

SOLID TUMOR

MELANOMA

Individualized NeoAntigen Specific Immunotherapy (iNeST)

(RG6180)f

SOLID TUMOR

PD1 x TIM3

(RG7769)

LUNG

MELANOMA

SOLID TUMOR

Tiragolumab
(anti-TIGIT MAb)

(MTIG7192A, RG6058)

SOLID TUMOR

HEMATOLOGY

IL5/IL15Ra-Fc

(RG6323)

SOLID TUMOR

aDeveloped in collaboration with Array BioPharma. bIgnyta, Inc acquisition. cJoint project with AbbVie. cDeveloped in collaboration with Exelixis. eDeveloped in collaboration with Chugai. fDeveloped in collaboration with BioNTech.
Current as of April 22, 2020. The trial information is taken from ClinicalTrials.gov.

Reference